



[Home](#) / [Investors](#) / [News Releases](#)

# Insmmed Announces Upcoming Data Presentation at AMCP Nexus 2015

BRIDGEWATER, N.J., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Insmmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases today reported new nontuberculous mycobacteria (NTM) lung disease research will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2015 taking place in Orlando from October 26-29.

Summarized below is the poster title and presentation time. Additional information about the meeting can be found on the AMCP Nexus 2015 website at <http://www.amcpmeetings.org/>.

**Presentation Title:** Pulmonary Nontuberculous Mycobacterial Infections: Healthcare Resource Utilization and Costs in Medicare Patients at a US Health Plan

**Lead Author:** K. Abraham

**Poster Number:** A01

**Date:** Tuesday, October 27, 2015

**Session Time:** 4:00-5:45 PM ET

The poster will be made available on Insmmed's website after presentation at the meeting.

## About Insmmed

Insmmed Incorporated is a global biopharmaceutical company focused on the needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that can lead to progressive inflammation and lung damage. There are no currently approved treatments for NTM in the United States or European Union (EU). In the EU, the company has filed a marketing authorization application seeking approval of ARIKAYCE for use in patients with NTM, as well as in cystic fibrosis patients with *Pseudomonas aeruginosa* lung infections. Insmmed's earlier-stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company is developing for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. To complement its internal research, Insmmed actively seeks in-licensing opportunities for a broad range of rare diseases. For more information, visit [www.insmed.com](http://www.insmed.com).

---